Status:
RECRUITING
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
National Institute on Aging (NIA)
Conditions:
Demyelinating Disorders
MCI
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheim...
Eligibility Criteria
Inclusion
- Inclusion:
- Male and Female subjects must be ≥18 and \<90 years of age;
- Able to understand and provide informed consent prior to study procedures
- Must be in good health
- Exclusion:
- Less than 18 years of age;
- Pregnant or breastfeeding;
- Any significant systemic illness or unstable medical condition;
- Pre-existing medical conditions or claustrophobic reactions;
- Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);
- History of a bleeding disorder or are currently taking anticoagulants.
Exclusion
Key Trial Info
Start Date :
May 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 5 2030
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT06999434
Start Date
May 5 2025
End Date
May 5 2030
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University PET Center
New Haven, Connecticut, United States, 06510